Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Equity earnings (loss) in AmerisourceBergen

Impairment of goodwill

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Walgreens

Duane Reade is a subsidiary of Walgreens Boots Alliance, is a chain of pharmacy and convenience stores, primarily located in New York City, known for its high volume small store layouts in densely populated Manhattan locations.

Duane Reade

Boots UK is a pharmacy chain in the United Kingdom, Ireland, Norway, Thailand and other territories. Boots became a subsidiary of the new company, Walgreens Boots Alliance, on 31 December 2014.

Boots UK

Alliance Healthcare was formerly Alliance UniChem, wholesales, distributes, and retails pharmaceutical, surgical, medical, and healthcare products throughout Europe. The company supplies more than 110,000 pharmacies, doctors, health centres and hospitals from over 288 distribution centres in 11 countries. The company is a wholly owned subsidiary of Walgreens Boots Alliance, which was formed by the merger of Walgreens with its former parent Alliance Boots in 2014. Alliance Boots had itself been formed in 2006 by the merger of Boots Group and Alliance UniChem on 31 July 2006. Alliance UniChem was rebranded Alliance Healthcare in 2009.

Alliance Healthcare

Walgreens Boots Alliance, Inc. engages in the provision of healthcare and retail pharmacy services. It operates through the following segments: United States Retail Pharmacy, International, and United States Healthcare. The US Retail Pharmacy segment includes the operation of retail drugstores, health and wellness services, specialty and home delivery pharmacy services, and equity method investment. The International segment offers pharmacy-led health and beauty retail businesses outside the US and the pharmaceutical wholesaling and distribution business in Germany. The US Healthcare segment delivers improved health outcomes and lower costs for payors and providers through owned and partnered assets. The company was founded by Charles R. Walgreen and John Boot in 1909 and is headquartered in Deerfield, IL.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Walgreens reports Q1 earnings decline, eyes growth opportunities ahead

Walgreens faces challenges from COVID impacts and investments but is on track to achieve full-year guidance.
Strategic acquisitions and scaling U.S. Healthcare present opportunities for growth and profitability.
Despite first-half declines, the company anticipates improvements in margins and performance in the second half.
Efforts to optimize cash flow and investments position Walgreens for future growth and success.

Walgreens reports 4.5% sales growth in Q2 2023 earnings

Walgreens remains cautiously optimistic about managing potential changes in health plans and anticipates a strong second half of the year. The company is targeting debt reduction and small tuck-on acquisitions in healthcare as capital allocation priorities.

Walgreens (WBA) reports mixed Q3 performance, focuses on profitability

Walgreens (WBA) Q3 2023 earnings call highlights mixed performance with a focus on profitability enhancement.
Strategic partnerships, cost management programs, and capital allocation priorities support long-term value creation.
Challenges in margin pressures, script growth, and operational issues require immediate actions for profitability.
Opportunities lie in unlocking profitability, market developments, and demand for risk-based health care services.

Walgreens appoints new CEO to drive cost savings and script growth opportunities

Walgreens is strategically positioning itself for operational efficiency and cost savings in fiscal year 2024. The company's new CEO, Tim Wentworth, is expected to drive healthcare expertise and cost-effective outcomes. Despite challenges like lower contributions and segment declines, Walgreens is leveraging opportunities for script growth and financial improvement.

Walgreens Q1 Earnings: Navigating Challenges, Focused on Value Creation

Walgreens is navigating challenges in the pharmacy sector while focusing on strategic initiatives to drive value creation and sustainable growth. The company's emphasis on partnerships, cost-saving actions, and a shift towards value-based reimbursement models positions them for future success in the evolving healthcare landscape.

Walgreens reports solid Q2 results, focuses on growth strategies

Walgreens navigates retail challenges with strong operational performance. Focus on cost discipline, portfolio optimization, and cash flow improvement. Strategic decisions to drive growth and unlock value in healthcare areas.

Walgreens Q3 Earnings Miss Expectations Amid Challenges

Walgreens' Q3 2024 earnings call highlighted a challenging quarter with missed expectations, driven by pressures in the retail pharmacy sector and adverse market conditions. CEO Tim Wentworth emphasized ongoing strategic reviews and cost management initiatives as key to navigating these challenges. The company remains committed to transforming its business model to better serve customers and improve operational efficiency.

Walgreens (WBA) reports Q4 earnings, focuses on growth strategies

Walgreens (WBA) focused on financial stability, cost efficiency, and strategic growth initiatives in Q4 2024 earnings call.
The company aims to address challenges like disruptions, inflation, and underperforming stores while leveraging strengths in cash flow and cost-cutting.
Opportunities in store optimization, digital enhancement, and asset monetization are key areas for future growth.
Overall, Walgreens is navigating challenges, leveraging strengths, and pursuing opportunities to enhance financial performance and resilience.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, NY / ACCESSWIRE / July 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Walgreens Boots Alliance, Inc. ("Walgreens Boots Alliance, Inc.") (NASDAQ:WBA) concerning possible violations of federal securities laws. On June 27, 2024, following CEO Rosalind Brewer's abrupt resignation in September 2023, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024.

Walgreens Boots Alliance, Inc. (WBA) Shareholders May Have Been Affected by Fraud- Levi & Korsinsky Investigates

NEW YORK CITY, NY / ACCESSWIRE / July 10, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Walgreens Boots Alliance, Inc. ("Walgreens Boots" or "the Company") (NASDAQ:WBA). Investors who purchased Walgreens Boots securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/WBA.

WBA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Walgreens Boots Alliance, Inc. and Encourages Investors to Contact the Firm!

WBA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Walgreens Boots Alliance, Inc. and Encourages Investors to Contact the Firm!

Agree Realty

Broadstone Net Lease

EPR Properties

Essential Properties Realty Trust Inc

Four Corners Property Trust

Gaming and Leisure Properties

Global Net Lease

Gladstone Commercial

Gladstone Commercial Corp 7 1/2 % Cum Red Pfd Shs Series B

Getty Realty

National Retail Properties

NETSTREIT Corp

Realty Income Corp

Alpine Income Property Trust

Vici Properties

W. P. Carey

Thinking outside the box involves looking at problems from a different perspective, such as using virtual reality to stimulate creativity. Realty Income has grown into a $73 billion REIT by thinking outside the box and expanding into various property sectors. Evaluating cost of capital is crucial for REITs to create value, with lower costs allowing for higher quality investments.

Thinking Outside The (Net Lease REIT) Box

Walgreens' stock continues to hit new lows because investors aren't convinced the business is on the right path. The company is turning a profit but its margins are razor-thin.

Walgreens Boots Alliance Stock Hits 27-Year Lows. Has It Become a Steal of a Deal?

NEW YORK, NY / ACCESSWIRE / July 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Walgreens Boots Alliance, Inc. ("Walgreens Boots Alliance, Inc.") (NASDAQ:WBA) concerning possible violations of federal securities laws. On June 27, 2024, following CEO Rosalind Brewer's abrupt resignation in September 2023, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024.

ATTENTION Walgreens Boots Alliance, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights

LOS ANGELES, CA / ACCESSWIRE / July 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

WBA Investors Are Urged By The Schall Law Firm To Participate In The Inquiry Into Suspected Securities Fraud At Walgreens Boots Alliance Inc

Walgreens Boots Alliance, Inc. Being Investigated on Behalf of Walgreens Boots Alliance, Inc. Investors. Contact Levi & Korsinsky For Details

WBA stock drops 57% YTD, hitting 27-year lows, amid disappointing Q3 results and profit outlook cuts. Challenging environment with weak consumer spending and inflation pressures are impacting Walgreens' performance. Despite facing cash flow crisis and restructuring, WBA posts 2.6% sales growth driven by robust healthcare segment performance.

Walgreens: Here's What Comes Next

The Walgreens (NASDAQ: WBA) stock price has fallen apart. It has crashed in the past three consecutive weeks and moved to its lowest point since 1998.

Walgreens stock price analysis: could it go bankrupt?

Moderna

Cassava Sciences Inc

The outlook of many healthcare stocks is quite positive at this point. That's partly because many large investors have shunned the sector, since they believe that it is destined to produce horrible returns as long as interest rates remain elevated.

3 Healthcare Stocks to Sell in July Before They Crash & Burn

LOS ANGELES, CA / ACCESSWIRE / July 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages WBA Shareholders To Join The Investigation Into Alleged Securities Fraud At Walgreens Boots Alliance Inc

This pharmacy stock is down 54% on the year. It trades at less than four times this year's earnings.

Should You Buy the 1st Half's Worst-Performing S&P 500 Stock?

NEW YORK, NY / ACCESSWIRE / July 7, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Walgreens Boots Alliance, Inc. ("Walgreens Boots Alliance, Inc.") (NASDAQ:WBA) concerning possible violations of federal securities laws. On June 27, 2024, following CEO Rosalind Brewer's abrupt resignation in September 2023, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024.

Walgreens Boots Alliance, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - WBA

LOS ANGELES, CA / ACCESSWIRE / July 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Urges WBA Shareholders To Be Part Of The Probe Into Presumed Securities Fraud At Walgreens Boots Alliance, Inc.

Walgreens reported third-quarter earnings below expectations and lowered guidance. Negative retail pharmacy industry trends continue to weigh on margin.

Why Walgreens Boots Alliance Plunged in June

CVS Health

Pfizer

Uncovering bargain stocks poised for substantial growth is hard. Understanding which stocks to buy can significantly impact investment success as the world navigates through the complexities of market trends and economic landscapes.

3 Bargain Stocks With the Potential for Mind-Boggling Returns

NEW YORK, NY / ACCESSWIRE / July 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Walgreens Boots Alliance, Inc. ("Walgreens Boots Alliance, Inc.") (NASDAQ:WBA) concerning possible violations of federal securities laws. On June 27, 2024, following CEO Rosalind Brewer's abrupt resignation in September 2023, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024.

Walgreens Boots Alliance, Inc. (WBA) Investors with Losses are Urged to Contact Levi & Korsinsky to Discuss Their Rights

WBA ACTIVE INVESTIGATION: Contact Levi & Korsinsky if you lost money on your Walgreens Boots Alliance, Inc. investment

LOS ANGELES, CA / ACCESSWIRE / July 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Encourages WBA Stakeholders To Participate In The Investigation Into Alleged Securities Deception At Walgreens Boots Alliance, Inc.

NEW YORK, NY / ACCESSWIRE / July 5, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Walgreens Boots Alliance, Inc. ("Walgreens Boots Alliance, Inc.") (NASDAQ:WBA) concerning possible violations of federal securities laws. On June 27, 2024, following CEO Rosalind Brewer's abrupt resignation in September 2023, Walgreens announced 3Q24 financial results and reduced its revenue guidance for the fourth quarter and full fiscal year 2024.

Shareholders that lost money on Walgreens Boots Alliance, Inc. (WBA) should contact Levi & Korsinsky about Securities Fraud Investigation - WBA

LOS ANGELES, CA / ACCESSWIRE / July 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Walgreens Boots Alliance, Inc. ("Walgreens" or "the Company") (NASDAQ:WBA) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Invites WBA Investors To Join The Inquiry Into Suspected Securities Fraud At Walgreens Boots Alliance, Inc.

An Investigation Has Commenced on Behalf of Walgreens Boots Alliance, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your WBA Losses.

Bristol-Myers

AT&T

Verizon

24/7 Insights Wounded blue chip stocks can offer huge total return potential.

Jump on These 5 Ultra-High-Yield Pound-the-Table Stock Buys Now

Intel

Lululemon Athletica

Walgreens Boots Alliance's new CEO faces an uphill battle in turning the business around; margins are poor and growth is minimal. Lululemon Athletica's high valuation at the start of the year might have played a big role in the stock's steep sell-off since then.

News for Walgreens Stock (WBA)